| DB ID | MyCo_1725 |
| Title | Hypoxia promotes danger-mediated inflammation via receptor for advanced glycation end products in cystic fibrosis |
| Year | 2013 |
| PMID | 24127697 |
| Fungal Diseases involved | Fungal Pneumonia |
| Associated Medical Condition | Hypoxia and Cystic Fibrosis |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | Experiments were performed according to the Italian Approved Animal Welfare Assurance 245–2011-B. |
| Site of Infection | Lungs |
| Opportunistic invasive | Opportunistic |
| Sample type | Biopsy |
| Sample source | Lung Tissue Homogenate |
| Host Group | Animal |
| Host Common name | Mice |
| Host Scientific name | Mus musculus |
| Biomarker Name | S100B |
| Biomarker Full Name | S100B |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Italy |
| Cohort | Six- to eight-week C57BL/6 mice were purchased from Charles River (Calco, Italy). Genetically engineered homozygote Cftr2/2 mice (7) were bred at the CF core animal facility at San Raffaele Hospital, Milan. |
| Cohort No. | 7 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | In patients with cystic fibrosis (CF), lung disease is the major cause of morbidity and mortality. The progressive decline of pulmonary function is caused by a vicious cycle of airways infection and inflammation. The pulmonary immune response in CF is characterized by an early and nonresolving activation of the innate immune system, which is dysregulated at several levels, does not result in enhanced bacterial clearance, and plays a pivotal role in the pathogenesis of lung disease in CF. This is supported by several studies that have documented an altered balance of inflammatory and antiinflammatory cytokines in CF, such that targeting specific inflammatory and anti-inflammatory pathways may represent a valid therapeutic strategy in CF. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | Quantikine Human RAGE Immunoassay kit (R&D Systems, Minneapolis, MN), ELISA, human S100B ELISA KIT (Millipore, Billerica, MA) |
| Assay Data | None |
| Validation Techniques used | ELISA, Hypoxyprobe Treatment, Western Blotting, Immunohistochemistry, RT-PCR |
| Up Regulation Down Regulation | UP regulated |
| Sequence Data | S100B - Human (GenBank: M59486) and murine (GenBank: NC_000076.5) |
| External Link | None |
